Tag: dry age related macular degeneration
-
Novartis Fights Use of Low-Cost Option that Rival Its AMD-Fighting Lucentis Drug
Novartis is fighting against the use of a low-cost drug option, which rival its Lucentis eye medication, in various portions of Britain, reported Reuters. Lucentis brings in annualized sales worth around $2bn and is an age-related mascular degeneration (AMD) medication that is recommended by the National institute for Health and Clinical Excellence in Britain, according […]
-
Bascom Palmer to Host AMD Clinal Trials
Bascom Palmer Eye Institute has received IRB (institutional review board) approval for becoming the third clinical testing site in the U.S. for Advanced Cell Technology’s (ACT) embryonic stem cell-derived retinal pigment epithelial cells in treating dry age-related macular degeneration. Bascom Palmer Eye Institute, located in Miami and voted eight years in a row as the […]